Chinese medicinal composition for treating tristimania

Abstract

The invention discloses a Chinese medicinal composition for treating tristimania, which is prepared into certain formulations by taking curcuma longa, St John's wort and ginseng as raw materials, and extracting and separating the raw materials by using 0-75 percent ethanol. An animal toxicity test result shows that 284 times of an adult dosage of the medicinal composition for lavaging a mouse causes no acute toxicity reactions; a pharmacodynamic study shows that the medicinal composition can significantly perform antagonism on acinesia and hypothermia, induced by reserpoid, of a tristimania model mouse, and can increase the number of autonomic activities and the dead time for tail suspension and swimming, induced by the tail suspension and forced swimming, of a desperate animal model. A clinical research result shows that by adopting a Hamilton rating scale for depression (HAMD) to evaluate the depression severity which serves as the primary therapeutic effect index, a treatment groupobtains a significant curative effect, the effective rate is 92.3 percent, and compared with a control group, the medicinal composition has significant differences but has no toxic and side effects. The medicinal composition can be prepared into medically acceptable oral preparations, such as tablets, capsules (soft capsules or hard capsules), granules and the like; and the clinical curative effect and the pharmacodynamic study prove that the medicinal composition has the functions of smoothing the liver to alleviate mental depression and relieving mental stresses, and is an effective specialmedicament for treating the tristimania.

Description

technical field [0001] The invention belongs to the technical field of medicine, and relates to a medicine for treating depression, in particular to a traditional Chinese medicine composition composed of turmeric, hypericum perforatum and ginseng. Background technique [0002] Depression is a common emotional and mental disorder. With the acceleration of the pace of social life, depression has become a high-risk disease in today's society. According to the statistics of the World Health Organization in 2005, the prevalence of various depressions accounts for about 11% of the global population. According to the epidemiological survey in my country in 2003, there are at least 36 million depression patients in my country, of which only 5% of severe patients receive relevant treatment. Many patients with major depressive disorder commit suicide due to lack of regular treatment in time. According to the analysis of death data in 2003, at least 287,000 people in my country die b...

AI Technical Summary

Problems solved by technology

[0003] For the treatment of depression, Western medicine currently uses 5-hydroxytryptamine reuptake inhibitors, monoamine oxidase inhibitors, phenylpyrazine derivatives, 5-hydroxytryptamine-norepinephrine reuptake inhibitors, aminoketones, tricyclics, Seven types of antidepressants such as tetracycline pyrazine azepines, but most of the synthetic antidepressants have defects such as narrow antidepressant spectrum, large toxic and side effects, high drug price and easy relapse

Images